Admatop 2.5 Injection
Admatop 2.5 Injection is used in the treatment of ovarian cancer. It shows its working by stopping or slowing down the growth of cancer cells.
Admatop 2.5 Injection
Basic Information
Important information about this medicine
About This Medicine
General information about this product
Admatop 2.5 Injection is used in the treatment of ovarian cancer. It shows its working by stopping or slowing down the growth of cancer cells.
Admatop 2.5 Injection is used in the treatment of ovarian cancer. It shows its working by stopping or slowing down the growth of cancer cells.
Admatop 2.5 Injection is given as an IV infusion into vein by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
The most common side effects of this medicine include tiredness, vomiting, weakness, nausea, and abdominal pain. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Inform your doctor if you notice fever, chills, sore throat, and severe diarrhea. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.
Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
03Uses
Ovarian cancer
04How To Use
Your doctor or nurse will give you this medicine. Kindly do not self administer.
05How It Works
Admatop 2.5 Injection is an anti-cancer medication. It works by suppressing the activity of an enzyme (topoisomerase I) involved in DNA multiplication of the cancer cells. This slows the growth of cancer cells and eventually kills them.
06What If You Miss A Dose?
Q: What if you forget to take Admatop Injection?
A: If you miss a dose of Admatop 2.5 Injection, please consult your doctor.n
07Benefits
In Ovarian cancer
Ovarian cancer is a cancer that begins in the female organs that produce eggs (ovaries). This type of cancer is usually detected very late and can be fatal too. It usually spreads to the pelvis and stomach. Admatop 2.5 Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective medicine but has some side effects that may be bothersome. Consult your doctor to know about ways that can help you avoid these side effects.
08Side Effects
Tiredness
Vomiting
Weakness
Nausea
Abdominal pain
Indigestion
Decreased white blood cell count
Decreased blood cells (red cells, white cells, and platelets)
Diarrhea
Injection site reactions (pain, swelling, redness)
09Safety Information
Alcohol:SAFE
Consuming alcohol with Admatop 2.5 Injection does not cause any harmful side effects.
Pregnancy:CONSULT YOUR DOCTOR
Admatop 2.5 Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding:UNSAFE
Admatop 2.5 Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving:UNSAFE
Admatop 2.5 Injection may cause side effects which could affect your ability to drive.Admatop 2.5 Injection can make you feel tired and this may affect your ability to drive.
Kidney:CAUTION
Admatop 2.5 Injection should be used with caution in patients with kidney disease. Dose adjustment of Admatop 2.5 Injection may be needed. Please consult your doctor.Use of Admatop 2.5 Injection is not recommended in patients with end-stage kidney disease.
Liver:SAFE IF PRESCRIBED
Admatop 2.5 Injection is safe to use in patients with liver disease. No dose adjustment of Admatop 2.5 Injection is recommended.
10Drug Tips
Admatop 2.5 Injection helps treat ovarian cancer.
It is given by a drip into a vein (intravenous infusion).
Do not drive or operate machinery as Admatop 2.5 Injection may cause tiredness, drowsiness or weakness.
Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine.
Your doctor may get regular blood tests done to monitor your blood cells during treatment with this medicine.
Inform your doctor immediately if you notice any signs of infection such as fever, sore throat, rash or severe diarrhea.
References
Sources and references
Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1711-12.
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 951.
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1383.
Topotecan hydrochloride. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd.; 1996 [revised 23 Apr. 2018]. [Accessed 24 Jan. 2019] (online) Available from: View
Topotecan. Unterach, Austria: Ebewe Pharma; 1996 [revised Feb. 2014]. [Accessed 27 Mar. 2019] (online) Available from: View
Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from: View
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Topotecan. [Updated 2018 Dec 3]. [Accessed 19 Feb. 2020] (online) Available from: View
